Development code · Small Molecule
SEP-856
SEP-856 is a development code for Ulotaront (SEP-363856), developed by Otsuka Pharmaceutical Co., Ltd..
- Status
- Phase 2/3 for Generalized anxiety disorder
- Mechanism
- TAAR1 Agonist
- Developer
- Otsuka Pharmaceutical Co., Ltd.
Programs
- Ulotaront (SEP-363856) for Generalized anxiety disorderPhase 2/3Completed
- Ulotaront (SEP-363856) for Major depressive disorderPhase 2/3Completed
Also known as
- SEP-363856
- ulotaront